Replies to post #242516 on Biotech Values

[usma67korea]

Yea I thought of that but at this SUB 1B Enter. Value, should Covid program (regardless of results) have such a decimating impact on the valuation?

I had thought given the royalty stream and cash level, of all bio land, ENTA would hold up better than others, but it actually has been worse or at least as bad as other small/med bios